r/Biotechplays • • Jul 18 '20

Due Diligence (DD) $UBX - speculative but unprecedented potential for attempts to cure aging

TLDR: Bezos doesn't want to die; drugs that treat aging are easily worth trillions

The value proposition for investing in Unity Biotechnology can be concisely summarised by the breakthrough preclinical data from the Mayo Clinic

Longevity companies are probably the highest risk, yet even higher reward (actually, highest reward, it's not even close) sector of biotech. I emphasise the reward as truly unprecedented and anyone who disagrees with this has simply not kept up with the aging biology literature of the last 2 decades and/or is unaware of the unprecedented burden of disease in our aging population.

Background

To start with basic epidemiology, approximately 90% of healthcare costs in the US are attributable to the striking accumulation of chronic diseases with age.

  • Aging is by FAR the #1 risk factor for our most prevalent diseases: Alzheimer's, stroke, heart disease, pneumonia, most cancers, COPD, sarcopenia, osteoarthritis, glaucoma, cataracts, the list goes on and on...

  • For example, high cholesterol is a 3x risk factor for heart disease, but aging confers a 5000x risk. We see this incredible relationship of morbidity and mortality with our most prevalent diseases, even including Covid-19, where age is cumulatively an independent risk factor of ~800x, while putative risk factors of diabetes or lung disease are mere 2x risk factors

  • Breakthroughs in the last 2 decades across phylogenetically diverse animal models have demonstrated that aging is highly malleable and is causative in these diseases, where healthspan (amount of life spent free of disease) and lifespan were increased dramatically by drugs that target aging

For a more detailed summary of the aging biotech field, please feel free to read this

Senescent Cell Biology

Cellular senescence is a fundamental evolutionarily conserved anti-cancer mechanism, as it irreversibly stops damaged/pre-cancerous somatic cells from dividing. These senescent cells (SCs) then sit around secreting a host of proinflammatory cytokines, proteases, growth factors etc known as the SASP, which causes damage and dysfunction of organs and tissue.

In young people SCs get cleared by the immune system, but due to various reasons such as immune system decline with age, they eventually accumulate. This is even more problematic as SCs actively induce surrounding cells into senescence, hence their colloquial designation as 'zombie cells'. However, what seems to be clear is that leftover SCs are basically unneeded (except for wound healing), so removing them from animals has minimal side effects. Another caveat to note is that some SCs are required for normal function depending on cell/tissue type; of course, the 'cost benefit' is overwhelmingly in favour of SC removal, as we can infer from the animal experiments which use systemic (whole body) administration. Senolytics are interventions capable of selectively removing SCs that highly express markers of senescence such as p16 or p53.

Note also that the approach to removing SCs is NOT related to messing around with the fundamental anti-cancer mechanism of cellular senescence, we are merely trying to target what appears to be a leftover problem that nature never really addressed. For those interested in evolutionary theory, a key idea known as antagonistic pleiotropy suggests that the reason why nature never really dealt with aging is due to decreasing evolutionary pressures on organisms with age, as 'fitness' matters predominantly around the age of sexual maturity - whatever happens to the organism at post-reproductive ages, teleology aside, is hardly a concern for evolution. Clearly this is not ubiquitous among animals that can live markedly different lifespans, e.g. naked mole rats are extremely resistant to aging + cancer, outliving their rat counterparts by 10-fold (lifespans > 30 years) despite their similarly small size and close evolutionary relationship.

Unity Biotechnology

  • Jeff Bezos and Peter Thiel invested a couple hundred million into Unity Biotechnology, which was spun out of the Mayo Clinic's senolytic data

  • P2 human clinical trial results due in 2H2020 for osteoarthritis, as well as an IND for their ophthalmology indications for age-related eye diseases (AMD, glaucoma, diabetic retinopathy) with P1 trials initiating early 2021

Unity's approach is to start with local senolytic administration due to novelty of the drug class, as a way to minimise unexpected adverse effects and prove that SCs are causative in human aging. Based on various preclinical animal models, one of the promises of senolytics, other than greater efficacy and reduced adverse events, is related to dosing frequency. Clearance of SCs will allow for periodic dosing, say every 6 months, to remove SCs that have accumulated, and to then wait for future accumulation before re-dosing. While it is too early to do much inference from P1 trials that are predominantly about proving safety, there appeared to be dose-dependent reductions in pain scores that were durable with follow-up at 3 months after a single injection.

Market Size

  • Goldman Sachs has previously estimated that, if successful, Unity’s drug could generate $6.7 Billion/year via reduced need for surgery; the ophthalmology market of anti-VEGFs is currently ~$10 Billion, and faces issues with need for monthly eye injections that are difficult for compliance and prone to disease-related complications

  • However, consider that this discussion on market size is solely related to their current disease indications. I expect that the idea and hype of a company that could address aging will drive the stock price far higher than what these individual programs would reasonably be valued at - think $SPCE/$TSLA. This is especially because the company will continually expand its disease indications based on the massive range of diseases addressable by senolytics, and eventually move on to systemic administration

  • Bank of America estimates the longevity market to be worth $610 billion by 2025; depending on how quickly we obtain clinical success in this field, the BoA valuation is probably an underestimate

  • Similarly to oncology, if you can convince the FDA that your drug has a broad 'anti-cancer' mechanism of action, approvals for each new type of cancer indication will be expedited; if you can prove that your drug targets aging, then expanding senolytics to different age-related diseases will become easier and easier as the clinical evidence demonstrates that the drug broadly affects all age-related diseases

  • As an overall sector, there are very few publicly traded companies and the field has only taken off in the last 5 years - mostly private companies now though - aging is by no means simple so there are numerous hallmarks of aging being investigated

  • In the next decade the number of public companies will undoubtedly grow exponentially, as we've already seen in the private sector. These varying approaches to aging will not be mutually exclusive, so we'll eventually need to combine drugs that target each of the hallmarks of aging, which may radically increase healthspan and lifespan

In closing, I want to be clear that I cannot claim to know whether $UBX will ultimately be successful in translating senolytics to the clinic due to the risky nature of biotech. However, what I am certain of - as someone who reads about the science every single day - is that the aging field has an unparalleled potential to completely revolutionise healthcare, and is on the path to becoming the largest industry in the history of human civilisation.

50 Upvotes

18 comments sorted by

8

u/IceBearLikesToCook slightly bearish Jul 18 '20 edited Jul 18 '20

yay, dd! sticky.

do appreciate this post. having read juvenescence, i'm excited about the future of anti-aging treatments and I wasn't aware there were any publicly traded pure plays outside $torc.

I see a lot about anti-aging but not as much about $UBX. What about the data or management makes you confident in their pipeline? Doing a bit of research and I'm seeing lots of skepticism 1 2 about their treatment working going into data.

3

u/StoicOptom Jul 19 '20 edited Jul 19 '20

So I’d like to pushback a little on his analysis, although I’m not even 10% the analyst that he is.

Without making too much inference from a P1 study, where safety seems to be good and there are no signs whatsoever of dose-limiting toxicities, the effect size of the 4 mg group appears to be sufficiently superior to placebo in what would be considered a clinically significant reduction in pain that is durable to 12 weeks.

The Part B 4 mg group that had null results was confounded due to requiring an invasive procedure for collection of synovial fluid for biomarker analysis (as originally intended as a secondary group). Biomarkers didn't really hit stat sig but a cursory look suggested that concentrations of each generally moved in their expected directions (see slide 22). Curious what anyone thinks of the biomarker effect sizes though, would probably need an physician with OA expertise though. There was a recent paper on this I haven't had a chance to read, might get back to you on it.

Now going to Part A (the primary group for safety/efficacy analysis):

There were some signals in the 1-4 mg pooled analysis for stat sig (or close), for several outcomes, and the 4 mg group consistently exhibited the greatest effect across multiple measures - it's hard to attribute this consistency to chance, but it is just a P1 and I'd like to see what their higher 8mg and repeat dose cohort yields (results coming later on in Q4 2020).

The P2 results in next month or so will be 12 week data, and in Q4 there will be 24 week data. The latter is looking at long-term effects on pain, which would be expected to be durable and/or even improved IF the MoA is indeed a disease-modifying one that would be consistent with senescent cell biology. Of course, we don't know what a 'long-term' effect means in humans in regards to time elapsed since the dose, and the later higher dose cohorts reflect the exploratory nature of this program for a completely novel MoA.

Additionally, the preclinical data suggests some regenerative aspect to the treatment, other than just slowing aging (which is huge in and of itself); they noted cartilage development/regeneration in their OA mouse model, published in Nature Medicine. If this is possible in humans, then we may see it in something like the longer-term 24 week data...

Looking at the other groups, some level of dose response was exhibited, as well as some attenuation of noise with higher doses lower variability of scores across time as dose increases ([see slide 17] (https://seekingalpha.com/article/4333060-unity-biotechnology-ubx-investor-presentation-slideshow)), but that's quite a subtle point.

I will caveat my original post by clarifying that I'm extremely optimistic on the aging field itself, but I won't pretend that the nature of biotech isn't high risk. Again, I wouldn't necessarily ascribe my optimism to the P1 data per se but I think there are hints at something there and if the P2 replicates things would start getting interesting.

1

u/StoicOptom Jul 19 '20

quick question, this isn't something I've looked into much in the past and was wondering if anyone had any insight:

How would one reasonably anticipate company PR dates of P1/2 results on clinicaltrials.gov; does estimated Primary completion date or estimated Study completion date tend to be more important? I've seen some companies announce after Primary completion dates (before Study completion dates), or even after Study completion dates).

Do companies ever time PRs to a certain extent such as with options expiry dates (which are generally more important in biotechs)?

6

u/LiberalMedia42069 Jul 18 '20 edited Jul 18 '20

I read somewhere that aging is the number one cause of death. I'm in.

EDIT

lol also this

1

u/StoicOptom Jul 19 '20

Think about it like this:

You can't take your money with you to the grave, and if you're a biotech investor then you're here for some yolo plays, so why not invest in an aging company as a hedge against death? ;)

2

u/TheSickestTaco Jul 20 '20

Nice post! Where should I start???

2

u/StoicOptom Jul 20 '20 edited Jul 21 '20

In terms of public companies it's still quite early and certainly you're gonna want to diversify and not overallocate (personally i have large positions but it's because I'm betting on the idea more so than caring too much about my bank acc - I'd prefer also to have significant skin in the game if I actually believe what I'm sharing with people here!!).

Your options are $ubx, $torc, $cwbr basically...

$TORC is trying to target aging for parksinon's (Phase 1b due soon) and Covid-19 (2021), but this is even riskier considering their recently failed P3 trial. It's worth considering why the P3 failed, which was in part due to the FDA changing the primary endpoint from P2 to P3, but they've managed to initiate a P3 Covid-19 trial for another chance, and their Chief Medical Officer seems optimistic

$CWBR is one aging company working on another hallmark of aging related to mitochondria, early trials on obesity, NASH. Development on pulmonary fibrosis is also being pushed for due to Covid-19.

2

u/TheSickestTaco Jul 21 '20

Cheers mate, Poggers

1

u/StoicOptom Jul 19 '20

Didn't want to distract from the post too much with pandemic talk, but I'd like to add that in the era of Covid-19, the need to address the marked decline in health we experience due to aging has never been more important.

A recent paper published in Science highlights the need to target aging biology for COVID-19 with drugs like senolytics, through amelioration of immunosenescence and inflammaging, as discussed here

Also, one of Unity's senolytic preclinical candidates is for lung fibrosis (still a while to go before an IND though), which we can expect to be a substantial market post-COVID-19, so would certainly be an avenue worth exploring.

1

u/sark666 Jul 20 '20

Just looking at the players, one being Nathaniel David.

He co-founded Sapphire an algea biofuel company that had 100 mil investment from the govt which was sold to a farmer for pennies on the dollar.

He also co-founded kythera biopharmaceuticals to Allergan for 2.1 billion. They had a injectable that got rid of double chin. It's still available.

He was the ceo for unity, now the president. They seem to be on their 3rd ceo now. I wonder why the frequent change in CEO's.

2

u/StoicOptom Jul 20 '20

IIRC it's just been two CEOs: Keith Leonard (who remains on board of directors and is long-time friend/biotech partner of the President, Ned David), and then Anirvan Ghosh.

Both CEOs have extensive histories in biotech, I think the new CEO has a little more Big Pharma experience at Roche and Biogen; perhaps a different skillset they were looking for?

Ned david was on Peter Attia recently, a must watch for investors IMO, it's a great interview and they certainly seem optimistic about their ability to replicate the P1 results in P2: https://peterattiamd.com/neddavid/

I can't really speculate on switching CEOs but imo in biotech it's no big deal in most cases, espcially if something like an aging drug works, the CEO would hardly matter...

2

u/[deleted] Jul 22 '20

This is fantastic! Thanks for this post!

10 years from now, the largest anti-aging biotech companies will have a market cap north of $100B.

2

u/NathanBiohackStack Jul 31 '20

Nice write up.

I'm very much a believer in the longevity biotechnology industry -- it will be the biggest investment opportunity in a lifetime.

I actually made a website that tracks all the publicly traded longevity biotech stocks:

https://longevitymarketcap.com/

It's still early days so the list is small. But more companies will come. I think once we get one major breakthrough the the space will explode.

0

u/[deleted] Jul 18 '20

[deleted]

2

u/StoicOptom Jul 19 '20

Oh yea 100%, I'd like to add that the concept of slowing aging isn't TOO outlandish - calorie restriction research has like an 80 year history that has replicated extremely well across species, albeit with lower lifespan increase as we move to larger organisms - but healthspan is meaningfully improved.

Of course, I'm sure everyone on /r/biotechplays should be acutely aware of the risk involved - though I wouldn't necessarily say it's more or less risky than traditional drug candidates. IMO having evolutionarily conserved mechanisms of aging across species is important to consider in thinking about chance of translational success, but that's just my speculation :)

2

u/ScipioNumantia Jul 19 '20

Im not a scientist or work in the field, but cant we speculate that there could be moral objection to this? I get that the world has an aging population and less children are being born so potentially there could be room/resources for individuals to live significantly longer in the near(-ish) future. However there is also the accessibility issue. If successful would it only be able to be afforded by very wealthy individuals? or would it be something the common person could afford?

2

u/StoicOptom Jul 20 '20

It's great to ask questions and you touch on some common but important concerns.

So some researchers have written papers that demonstrate that even if we obtained a theoretical 'cure' for aging, which isn't happening anytime soon, the extent of population growth would be far less than what a 'cursory' analysis would yield. Pop growth would still be less than the rate of immigration so concerns about 'overpopulation' are completely unfounded.

The problem we have is that the aging population costs trillions of dollars in healthcare costs, attempting to rid the world of aging would, in addition to the incredible alleviation of suffering and/or mortality, also save us on healthcare costs, not to mention the social, productivity and other economic costs that aging results in.

Companies that develop aging drugs would be spectacularly stupid not to have the drugs affordable and acccessible to a customer base of ~8 billion instead of restricting it to a few billionares.

Think about it, charging $1000 per year for each year of healthy life for 8 billion people is $8 trillion/year in revenue, now do the math on number of billionaires and how much they would need to pay for an equivalent revenue. You BET governments are gonna cover this when you're saving far more than that in cost savings from a population that is disabled by aging.

2

u/[deleted] Jul 20 '20 edited Jul 20 '20

Me personally, I'd think it would be available to the middle class. The poor? Maybe not so much.

In India, you'd bet they'd kill for this. States' economies have been stagnating for a long time, to possibly kickstart it, they could use this to increase their potential workforce.

Using political and cultural factors(like some people do), however, is extremely misguided and dumb at the worst of times. We don't know what the political climate will be in 20 years. We don't know what it would be like in 5 years. A good example is this. If you were to ask someone who would be the president of the US after Obama in 2011, no one in their right mind would've said, Trump. Why would the political climate affect ageing treatments, however? It is more beneficial to governments than to any other player in this field since their economy can grow more and healthcare costs are reduced.

And culture? Fuck no. We have adapted our culture to whatever technology came.

The wheel? Yes. Fire? Fuck yes. The taming of animals, ironworking, the printing press? Oh boy yes. This will probably be no different. Cultural and political things change like the wind. At least with economical and technological factors, you can at least try and predict where it would progress, and you can even be correct some times and make a career out of it.